GSK Will Take Its HGS Bid Hostile; Will Shareholders Buy In?
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK plans to take its $13 per share offer straight to Human Genome Sciences shareholders after being turned down by the company last month.